GYRE
Gyre Therapeutics Inc.
7.00$
-0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -15.3% | +0.1% | -7.2% | +1.0% | +9.4% | -20.9% | +34.8% | +2.8% | +21.7% | -39.5% | +29.2% | – | |
| – | +5.6% | -21.7% | -21.3% | +24.4% | +22.9% | -24.0% | +28.7% | +41.4% | +7.1% | -29.6% | +80.0% | – | |
| – | -16.1% | +1.1% | -6.6% | +0.3% | +8.8% | -20.7% | +35.1% | +1.2% | +22.5% | -39.9% | +26.3% | – | |
| – | +51.8% | -52.2% | +53.8% | -17.3% | +33.8% | -16.6% | +169.8% | -71.7% | +103.8% | +39.9% | +184.0% | – | |
| – | +769.1% | -66.2% | +0.8% | +11.7% | +42.9% | -9.3% | +46.9% | -40.6% | +55.2% | +7.7% | +9.0% | – | |
| – | +549.6% | -84.6% | +16.9% | -4.2% | +28.6% | -27.6% | +63.2% | -28.6% | +60.5% | -13.3% | +34.6% | – | |
| – | -817.9% | – | -59.6% | +29.8% | -84.3% | +242.8% | -198.5% | – | -98.3% | -7,895.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -996.3% | – | -51.6% | -34.9% | -80.4% | +500.4% | -134.0% | – | -100.9% | – | – | – | |
| – | -81.0% | +264.2% | -41.2% | -28.3% | -81.1% | +343.8% | -26.5% | +155.7% | -23.2% | -147.8% | – | – | |
| – | -2,640.4% | – | -53.2% | -68.1% | -108.8% | – | -77.8% | +503.7% | -147.7% | – | – | – | |
| – | -142.9% | – | -51.4% | -29.8% | -74.3% | +355.9% | -123.8% | – | -92.4% | -1,461.7% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.